share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 30 21:09
Summary by Futu AI
康希諾生物於2023年年度報告中披露，公司實現營業收入3.57億元，同比減少65.49%，歸母淨虧損14.83億元，同比增虧63.04%，主營業務毛利率為26.50%，新冠疫苗產品銷售收入下降96.86%。公司根據新冠疫苗的實際及預期退貨情況，核算冲減收入2.53億元。此外，公司應收賬款餘額合計6.63億元，其中1年以上的應收賬款占比達27.80%，2022年對應占比為0.67%。公司解釋，新冠疫苗相關應收賬款回收較慢，導致1年以上應收賬款占比增加。至於公司的資金情況，2023年末公司貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。公司進行了外匯套期保值業務，以管理金融資產的匯率風險，並於報告期內實現收益1,569.10萬元。
康希諾生物於2023年年度報告中披露，公司實現營業收入3.57億元，同比減少65.49%，歸母淨虧損14.83億元，同比增虧63.04%，主營業務毛利率為26.50%，新冠疫苗產品銷售收入下降96.86%。公司根據新冠疫苗的實際及預期退貨情況，核算冲減收入2.53億元。此外，公司應收賬款餘額合計6.63億元，其中1年以上的應收賬款占比達27.80%，2022年對應占比為0.67%。公司解釋，新冠疫苗相關應收賬款回收較慢，導致1年以上應收賬款占比增加。至於公司的資金情況，2023年末公司貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。公司進行了外匯套期保值業務，以管理金融資產的匯率風險，並於報告期內實現收益1,569.10萬元。
DISCLOSED IN ITS 2023 ANNUAL REPORT, CONXINO BIO ACHIEVED OPERATING REVENUE OF $3.57 MILLION, DOWN 65.49% YEAR-ON-YEAR, NET MATERNITY LOSS OF $14.83 BILLION, A YEAR-ON-YEAR LOSS OF 63.04%, GROSS MARGIN FROM PRIMARY BUSINESS WAS 26.50%, AND SALES REVENUE FOR CORONAVIRUS PRODUCTS DECREASED 96.86%. Based on the actual and expected return of the COVID-19 vaccine, the company reported a revenue reduction of $2.53 million. In addition, the company's balance of accounts receivable totaled $6.63 billion, of which 27.80% of accounts receivable for more than 1 year and 0.67% in 2022, respectively. The company explained that the recovery of receivables related to the COVID-19 vaccine was slower, resulting in an increase in the proportion of receivables for more than 1 year. As for the capital situation of the company, the company...Show More
DISCLOSED IN ITS 2023 ANNUAL REPORT, CONXINO BIO ACHIEVED OPERATING REVENUE OF $3.57 MILLION, DOWN 65.49% YEAR-ON-YEAR, NET MATERNITY LOSS OF $14.83 BILLION, A YEAR-ON-YEAR LOSS OF 63.04%, GROSS MARGIN FROM PRIMARY BUSINESS WAS 26.50%, AND SALES REVENUE FOR CORONAVIRUS PRODUCTS DECREASED 96.86%. Based on the actual and expected return of the COVID-19 vaccine, the company reported a revenue reduction of $2.53 million. In addition, the company's balance of accounts receivable totaled $6.63 billion, of which 27.80% of accounts receivable for more than 1 year and 0.67% in 2022, respectively. The company explained that the recovery of receivables related to the COVID-19 vaccine was slower, resulting in an increase in the proportion of receivables for more than 1 year. As for the capital situation of the company, the company's monetary capital and transactional financial assets at the end of 2023 amounted to about $41.30 million, and short-term borrowings and long-term loans totaled about $19.20 billion. The company conducted a foreign exchange hedging business to manage the exchange rate risk of financial assets and achieved revenues of $1,569.10 million during the reporting period.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.